Course Videos
What insights have we gained about drug-based management of the diabetic heart?
What insights have we gained about drug-based management of the diabetic heart?
From a translational perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?
Are there significant clinical differences—pharmacokinetic, safety, degree of weight loss, control of PPG—between the two combination formulations, i.e. glargine insulin plus lixisenatide (iGlarLixi) vs. degludec insulin plus liraglutide (iDegLira)?
Why do clinicians managing patients with T2D need to be aware of the trials, physiologic basis, side effects and other dimensions of deploying fixed ratio, long-acting insulin-GLP-1 RA combination regimens?
How will fixed ratio, basal insulin-GLP-1 RA combinations likely fit into the sequencing algorithm for diabetes care? How do we select among the available options? And in whom should we use these formulations?
What are the ideal clinical profiles for and distinctions among the fixed ratio, combination formulations? What are their potential advantages and unique therapeutic windows of opportunities?
What advances in long-acting insulin and GLP-1 RA--and combination approaches--are having a positive impact on management of T2D? How should PK/PD properties affect our choice of specific GLP-1 RA?
From a practical, titration perspective what important clinical guidance can you provide to optimize effectiveness of the fixed ratio insulin-GLP-1 RA combination?
What level of HA1c reduction is achieved with the fixed ratio combination and how is the side effect profile of the GLP-1 RA affected by the combination formulation and the titration strategy it utilizes?
How would you approach a 65-year old patient with T2D who has reasonable control of FBG but clear documentation of PPG?
How would approach a mildly obese patient with T2D on a maximum dose of metformin who is not yet achieving FPG or PPG target goals?
Can you identify the specific composition of fixed ratio combination long-acting insulin/GLPA-1 RA formulations, and how clinicians should titrate and deploy these agents?